← All trials
NCT06982651
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 9, 2023
- Primary completion
- Mar 18, 2024
- Completion date
- Mar 18, 2024
- First posted
- May 21, 2025
- Last posted
- May 21, 2025
- Enrollment
- 98
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.